Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator of drug delivery platforms, is increasing the effectiveness of orally administered drugs. With oral absorption being the most convenient and widely used route for taking medications, decades of research have advanced the understanding of critical factors controlling oral bioavailability. Scientists are now better understanding the physiological function and formulation functionality that has been used in designing improved and more desirable oral medicine delivery through extensive research. Lexaria is accomplishing this through its patented DehydraTECH(TM) technology. “DehydraTECH improves the way that active pharmaceutical ingredients (‘APIs’) make their way into the bloodstream. This is achieved by promoting healthier ingestion methods and an increase in the effectiveness of fat-soluble active molecules,” explains a recent article. “Lexaria’s DehydraTECH can be summarized by these major benefits: speeds up delivery; increases bioavailability; increases brain absorption; improves drug potency; reduces drug administration costs; and masks unwanted taste. One of Lexaria’s recent human clinical trials (HYPER-H21-2) using DehydraTECH-processed cannabidiol (‘CBD’) evidenced reduced arterial stiffness. The discovery potentially broadens Lexaria’s application’s ability to treat cardiovascular and other diseases beyond hypertension.”
To view the full article, visit https://ibn.fm/LEnq3
About Lexaria Bioscience Corp.
Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce time of onset from one to two hours to minutes, and mask unwanted tastes. The technology is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 23 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.